Falconer, let's assume for purposes of discussion that both 2-73 and 1066 will be megablockbuster drugs. How could you account for one tiny company coming up with two such pharmaceuticals? The odds against just one are unreal.
A "plethora of pains"? You mean a variety, or several different. You assume the rat models prove human efficacy, just not safety. They prove neither. They show it is worth human testing.
The company may soon start developing the analgesic pipeline, now that it's getting the IP secured. That's good to see!
News 
Market Data 
Discover 
